Evidence map›Paper›PMID 33099540›Full record

ArticleAging2020

CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.

Yue Cui, Yang Song, Shi Yan, Mengru Cao, Jian Huang, Dexin Jia, Yuechao Liu, Shuai Zhang, Weina Fan, Li Cai and 2 more

Open access · greenAbstract read
In one paragraph

Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Mutation Spectrum ofInternational journal of molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. LRH1 Acts as an Oncogenic Driver in Human Osteosarcoma and Pan-Cancer.Frontiers in cell and developmental biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yue CuiThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yang SongDepartment of Orthopedic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Shi YanThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Mengru CaoThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Jian HuangThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Dexin JiaThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yuechao LiuThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Shuai ZhangThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Weina FanThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Li CaiThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Chunhong LiThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Ying XingThe Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Harbin Medical University · CNFourth Affiliated Hospital of Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains the most lethal cancer worldwide because of its high metastasis potential. Epithelial-mesenchymal transition (EMT) is known as the first step of the metastasis cascade, but the potential regulatory mechanisms of EMT have not been clearly established. In this study, we first found that low CUEDC1 expression correlated with lymph node metastasis in non-small cell lung cancer (NSCLC) patients using immunohistochemistry (IHC). CUEDC1 knockdown promoted the metastasis of NSCLC cells and EMT process and activated TβRI/Smad signaling pathway. Overexpression of CUEDC1 decreased the metastatic potential of lung cancer cells and inhibited the EMT process and inactivated TβRI/Smad signaling pathway. Immunoprecipitation (IP) assays showed that Smurf2 is a novel CUEDC1-interacting protein. Furthermore, CUEDC1 could regulate Smurf2 expression through the degradation of Smurf2. Overexpression of Smurf2 abolished CUEDC1 knockdown induced-EMT and the activation of TβRI/Smad signaling pathway, while siRNA Smurf2 reversed CUEDC1 overexpression-mediated regulation of EMT and TβRI/Smad signaling pathway. Additionally, CUEDC1 inhibited proliferation and promoted apoptosis of NSCLC cells.

Indexed as

Epithelial-Mesenchymal TransitionA549 CellsAnimalsApoptosisCarcinoma, Non-Small-Cell LungCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsLung NeoplasmsMice, Inbred BALB CMice, NudeNeoplasm InvasivenessCUEDC1 protein, humanIntracellular Signaling Peptides and ProteinsReceptor, Transforming Growth Factor-beta Type ISmad ProteinsSMURF2 protein, humanTGFBR1 protein, humanUbiquitin-Protein LigasesCUEDC1EMTmetastasisSmurf2TβRI/Smad signaling pathway

Identifiers

PMID33099540
PMCPMC7655170
OpenAlexW3038979456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.